treatment | Page 23 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

  1. Home

Pankit Vachhani, MD

Vachhani, Pankit
Assistant Professor of Medicine
University of Alabama Birmingham

Dr. Pankit Vachhani is an Assistant Professor of Medicine at the University of Alabama at Birmingham and Associate Scientist of Experimental Therapeutics. He graduated from Weill Cornell Medical College in Qatar in 2012 and on to complete his internal medicine residency at Virginia Commonwealth University, followed by a fellowship in hematology/oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. Clinical Interests & Research: At UAB, he is involved in multiple clinical trials as a principal investigator. He leads the Leukemia/BMT working group.

Online Profile: 
https://scholars.uab.edu/6176-Pankit-Vachhani

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation

Key Points
This study illustrates the survival benefits of abatacept combined with CNI/MTX in patients with hematologic malignancies undergoing HCT.

The addition of abatacept may provide an approach for alternative donor pool expansion when HLA-identical sibling donors are unavailable.

Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial

Summary
Background
Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to transplantation in this patient population.
Methods

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Several national agencies, including the American Society of Clinical Oncology (ASCO), recommend the prescription of exercise for patients diagnosed with cancer.1,2 The evidence base for this recommendation is derived from studies that showed exercise-related improvements in patient-reported outcomes (PROs), treatment-associated adverse effects, cardiorespiratory fitness (CRF), and overall physical functioning.3-6 Additionally, exercise may have direct anticancer effects and indirect effects by synergizing standard cancer therapies.7,8 Despite these benefits, the implementation of exercise